Want to see HK:0809 full AI Analyst Report?
Global Bio-chem Technology Group Co. Ltd. (0809) AI Stock Analysis
Top Page
Global Bio-chem Technology Group Co. Ltd.
(HKEX:0809)
The overall score is very low, driven primarily by poor financial health. The company is technically insolvent with negative equity and negative operating cash flow, despite headline revenue growth. Technical trends confirm sustained selling pressure, and the superficially low P/E ratio is misleading due to reliance on non-operating income.
Global Bio-chem Technology Group Co. Ltd. (0809) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 565.07M
- Dividend Yield
- ―
- Average Volume (3M)
- 467.59K
- Price to Earnings (P/E)
- 1.7
- Beta (1Y)
- 0.31
- Revenue Growth
- -8.40%
- EPS Growth
- -77.49%
- Country
- Hong Kong
- Employees
- 1,890
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Agricultural - Commodities/Milling
Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model
Company Description
Global Bio-chem Technology Group Company Limited, an investment holding company, manufactures and sells corn refined products and corn-based biochemical products in the People's Republic of China, Asia, the Americas, and internationally. It operates...
How the Company Makes Money
The company primarily makes money by manufacturing and selling corn-based biochemical products. Key revenue streams typically include: (1) sales of starch and modified starch products used as functional ingredients (e.g., thickeners, binders) in food...
Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview
Summary
Financial performance is weak. While revenue has recovered and net income is positive, the core business is unprofitable with negative EBIT and low gross margins. The balance sheet shows negative equity, indicating technical insolvency, and cash flow from operations is negative, highlighting unsustainable operations.
Income Statement
40NegativeBalance Sheet
35NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10B | 2.28B | 2.00B | 1.37B | 12.71M | 746.55M |
| Gross Profit | 38.16M | 196.44M | 218.68M | 43.64M | -263.37M | 48.35M |
| EBITDA | -152.25M | 578.15M | -37.66M | 4.76B | -409.26M | 785.63M |
| Net Income | 104.17M | 156.30M | 769.60M | 4.22B | -1.44B | -400.80M |
Balance Sheet | ||||||
| Total Assets | 4.88B | 4.62B | 4.54B | 5.21B | 5.85B | 6.48B |
| Cash, Cash Equivalents and Short-Term Investments | 126.34M | 94.44M | 85.47M | 315.41M | 41.77M | 109.13M |
| Total Debt | 1.86B | 1.79B | 3.69B | 5.45B | 8.91B | 8.44B |
| Total Liabilities | 5.69B | 5.14B | 6.50B | 9.25B | 13.64B | 13.18B |
| Stockholders Equity | -814.22M | -518.52M | -1.95B | -4.04B | -7.54B | -6.52B |
Cash Flow | ||||||
| Free Cash Flow | -56.10M | -28.39M | 76.04M | -94.24M | -94.19M | -501.02M |
| Operating Cash Flow | -22.02M | -7.35M | 76.04M | -50.46M | -88.01M | -475.21M |
| Investing Cash Flow | -34.09M | -21.04M | -535.00K | -14.37M | -413.00K | 392.59M |
| Financing Cash Flow | 16.09M | 33.57M | -76.06M | 112.62M | 109.75M | -48.66M |
Global Bio-chem Technology Group Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.37, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0809.
Global Bio-chem Technology Group Co. Ltd. Peers Comparison
Overall Rating
HK:231781Outperform
HK:183780.1Outperform
HK:388948Neutral
HK:383847Neutral
HK:084144Neutral- HK:080941Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2317 | 81Outperform | HKD 1.01B | 7.06 | 6.00% | 15.80% | 4.72% | 20.03% |
| HK:1837 | 80Outperform | HKD 2.98B | 7.97 | 18.48% | 5.07% | 33.56% | 59.06% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| HK:3889 | 48Neutral | HKD 96.57M | -0.64 | 38.51% | ― | -7.04% | 8.69% |
| HK:3838 | 47Neutral | HKD 1.03B | 48.72 | 0.45% | 5.51% | -5.24% | -95.65% |
| HK:0841 | 44Neutral | HKD 88.88M | -34.55 | -0.49% | ― | 30.41% | 98.08% |
| HK:0809 | 41Neutral | HKD 565.36M | 1.73 | -15.63% | ― | -8.40% | -77.49% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0809 | Global Bio-chem Technology Group Co. Ltd. | 0.34 | -0.45 | -56.33% | |
| HK:3889 | Global Sweeteners Holdings Limited | 0.05 | -0.04 | -43.82% | |
| HK:1837 | Natural Food International Holding Ltd. | 1.36 | 0.27 | 24.20% | |
| HK:2317 | Vedan International (Holdings) Ltd. | 0.67 | 0.10 | 17.49% | |
| HK:3838 | China Starch Holdings Limited | 0.18 | 0.00 | 0.00% | |
| HK:0841 | Asia Cassava Resources Holdings Limited | 0.15 | 0.02 | 16.92% |
Global Bio-chem Technology Group Co. Ltd. Corporate Events
Global Bio-chem launches upgraded boilers and coenzyme Q10 expansion in Jilin
Global Bio-chem Technology Group has completed a flagship boiler refurbishment project at its Dehui production site in Jilin Province and officially commissioned upgraded high-temperature and ultra-high-pressure boilers. The initiative is designed to...
Global Bio-chem interim loss widens as margins collapse
Global Bio-chem Technology reported unaudited interim results for the six months ended 30 June 2026 showing a sharp deterioration in profitability despite only a moderate decline in revenue. Revenue fell to HK$1.00 billion from HK$1.19 billion year-o...
Global Bio-chem announces sweeping board and management reshuffle
Global Bio-chem Technology Group Company Limited has announced a broad reshuffle of its top leadership and governance roles, including changes to the board, board committees, and senior management. The move realigns key positions such as chairman, ge...
Global Bio-chem Sets Out Board and Committee Structure
Global Bio-chem Technology Group Co. Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive members. The board structure reflects a mix of management and external oversi...
Global Bio-chem Sets Board Meeting to Review Interim Results and Possible Dividend
Global Bio-chem Technology Group Company Limited has scheduled a board meeting for 28 August 2026 to review the unaudited interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an interim divi...
Global Bio-chem Signs RMB1.5 Billion Counter-Guarantee Deal With Major Shareholder Nongfa
Global Bio-chem Technology Group Co. Ltd. has entered into a three-year counter-guarantee agreement with major shareholder Nongfa, under which the company will provide counter-guarantees backing Nongfa’s guarantees to financial institutions for...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 26, 2026